The US Patent and Trademark Office has granted ProSomnus a patent for its automated manufacturing process of medical devices used to treat obstructive sleep apnea.
ProSomnus’ US Food and Drug Administration (FDA)-cleared oral appliance therapy devices reposition and stabilize the jaw during sleep, improving airflow through a patient’s pharyngeal space. The devices consist of maxillary and mandibular aligners that are precision-manufactured with twin-mated posts and are digitally milled to be patient-specific, according to a press release from the company. Prescribed advancements can be achieved by removing the current upper- or lower-device arch and inserting the next arch in the mandibular advancement series.
“Our automated medical device manufacturing technologies, the subject of this patent and other patents in our portfolio, are an important component of what makes ProSomnus different. Every ProSomnus precision device is personalized and manufactured based on the anatomy and treatment plan for each patient,” says Len Liptak, ProSomnus co-founder and CEO, in a press release. “These patented technologies enable ProSomnus to service the rapidly growing demand for our precision sleep apnea devices without compromising the effectiveness, comfort, and consistency that healthcare providers and their patients require. The data generated from our digital manufacturing capabilities enable ProSomnus to continuously improve our processes, quality, and technologies.”
This latest patent allowance marks the third in the family, which includes previously issued patent numbers 10,213,280 and 9,808,327. ProSomnus’ intellectual property portfolio now includes 16 issued patents worldwide.